KEY POINTS
The U.S. Food and Drug Administration has approved Casgevy, the first gene-editing treatment to be marketed in the country.
Casgevy uses Nobel Prize-winning technology CRISPR to treat sickle cell disease, a blood disorder that affects about 100,000 Americans.
Vertex Pharmaceuticals and CRISPR Therapeutics co-developed the one-time treatment that will cost $2.2 million per patient.